Anticoagulation in Chronic Kidney Disease

General Principles of Dose Adjustment

The American College of Cardiology recommends that non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over vitamin K antagonists (warfarin) for patients with chronic kidney disease (CKD) stages G1-G4 1, 2
Dose adjustment is mandatory based on creatinine clearance (CrCl), not a standard reduction to 50% 1, 2
All NOACs have some degree of renal elimination and require careful monitoring as renal function declines 1, 3

No dose adjustment is necessary for most anticoagulants 2
Clinical decisions and treatment recommendations are similar to those for patients without CKD 2

Rivaroxaban: reduce from 20 mg once daily to 15 mg once daily (25% reduction, not 50%) 1, 2, 3
Edoxaban: reduce from 60 mg once daily to 30 mg once daily (50% reduction) 1, 2
Apixaban: maintain 5 mg twice daily, with reduction to 2.5 mg twice daily only if two or more of the following criteria are present: age >80 years, weight <60 kg, or serum creatinine >133 μmol/L 2, 3
Dabigatran: maintain 150 mg twice daily (110 mg twice daily outside the US for increased bleeding risk) 2, 3

Apixaban is preferred due to its lower renal clearance (27%) and superior safety profile as renal function declines 4, 5, 6
Apixaban: 2.5 mg twice daily 2, 6
Rivaroxaban: 15 mg once daily (may be used, but with a less favorable bleeding profile) 1, 2
Edoxaban: 30 mg once daily (50% renal clearance, may be considered as an alternative) 1, 2, 5
Dabigatran: contraindicated in Europe; in the US, 75 mg twice daily based on pharmacokinetic data only (80% renal clearance, avoid use) 2, 4, 5

Warfarin remains the anticoagulant of choice, although the decision to anticoagulate is strictly individualized 4
Apixaban 5 mg twice daily is approved in the US for stable patients on chronic hemodialysis, with reduction to 2.5 mg twice daily if the patient is ≥80 years old or weighs ≤60 kg 4, 6
NOACs should generally be avoided, except for apixaban in the US for patients on dialysis 2, 4

Apixaban: 27% renal clearance – least dependent on renal function 5
Rivaroxaban: 35% renal clearance – intermediate renal clearance 5
Edoxaban: 50% renal clearance – requires more rapid dose reduction 5
Dabigatran: 80% renal clearance – most dependent on renal function, avoid use in severe CKD 5

Renal function should be monitored at least annually in all patients with NOACs 5
For patients with CrCl <60 ml/min, more frequent monitoring is required (minimum frequency in months = CrCl/10) 5
Additional monitoring is necessary during acute illnesses (infections, heart failure) that may transiently affect renal function 5
Calculate creatinine clearance using the Cockcroft-Gault formula, do not rely solely on serum creatinine 2

Do not use dabigatran in severe CKD due to its high renal clearance (80%) and increased bleeding risk 5
Warfarin in advanced CKD may increase the risk of vascular calcification, calciphylaxis, and anticoagulant-associated nephropathy 4, 5
Plasma levels of NOACs may accumulate in severe CKD despite dose adjustments, increasing the risk of bleeding 5
Inconsistencies between FDA and EMA approvals for NOACs in severe CKD and dialysis 5
Regulatory authorities use creatinine clearance (CrCl) while many clinical guidelines use eGFR, potentially creating confusion in dosing recommendations 5